Peptides to Stack With Retatrutide: BPC-157, GHK-Cu, MOTS-C & Tesamorelin

Retatrutide is the strongest single metabolic peptide studied to date, and that strength is exactly why the "what do I run with it" question comes up. When a compound moves body weight as fast as retatrutide did in its Phase 2 trial ^[1], researchers start asking about the adjacent problems rapid change creates (soft-tissue recovery, skin, mitochondrial demand) and about mechanisms that sit outside the incretin pathway entirely.

This guide is an overview of the peptides most often discussed alongside retatrutide and the rationale researchers cite for each. It reports what the published literature describes. None of it is medical advice, none of these compounds is approved for human use in this context, and, the point worth repeating, no controlled human study has tested any of them combined with retatrutide. Read this as a map of the conversation, not a protocol.

What "stacking" actually means

In the research-compound world, "stacking" is shorthand for running more than one compound during the same window, each selected for a distinct mechanism. The logic is additive coverage: retatrutide handles the metabolic core, and a second peptide is chosen to address something retatrutide leaves untouched.

That framing matters because it rules out the common misread: that stacking means more of the same effect. Adding a second GLP-1-class compound to retatrutide would stack the same mechanism and the same side effects, not broaden coverage. The peptides discussed below are interesting precisely because they work through different pathways: tendon and gut repair, copper-dependent skin remodeling, mitochondrial energy signaling, and growth-hormone release. Whether combining them delivers real additive benefit is unproven; the rationale is mechanistic, and mechanistic plausibility is not the same as demonstrated effect.

The peptides discussed alongside retatrutide, at a glance

The table sorts the field by how much human evidence exists behind each. That gradient is the single most useful thing to hold onto: tesamorelin sits on controlled human trials, GHK-Cu on smaller human and cell studies, and BPC-157 and MOTS-C largely on animal models. "Discussed alongside retatrutide" and "proven to help when combined with retatrutide" are very different claims, and only the first applies to any of them.

BPC-157 and TB-500: the recovery and gut-repair pair

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Its preclinical literature, largely rodent studies, reports accelerated healing of tendon, ligament, muscle, and the gastrointestinal lining, along with effects on the gut-brain axis. ^[2] One frequently cited experimental finding is enhanced tendon-fibroblast outgrowth, survival, and migration, the cellular machinery of soft-tissue repair. ^[3]

The rationale in the retatrutide context is twofold. First, aggressive caloric restriction and reduced protein intake can blunt recovery, so a compound with soft-tissue-repair signaling is of interest to researchers tracking that. Second, retatrutide's most common side effects are gastrointestinal (nausea, diarrhea, constipation ^[1]), and BPC-157's most-studied domain is GI-lining integrity, which is why it surfaces in the same conversations.

TB-500 is the synthetic version of a fragment of Thymosin β4, an actin-regulating peptide involved in cell migration, angiogenesis, and wound repair. ^[4] It is almost always mentioned together with BPC-157 as a "recovery pair," on the theory that the two cover complementary steps of the healing cascade. The honest caveat for both: human efficacy trials are scarce to nonexistent, and the recovery claims rest on animal and mechanistic data, not on outcome studies in people, let alone in people also running retatrutide.

GHK-Cu: skin integrity during rapid weight loss

GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to copper) that occurs naturally in human plasma and declines with age. In cell studies and small human trials it has been reported to stimulate collagen and glycosaminoglycan synthesis, support wound healing, and improve several markers of skin remodeling and firmness. ^[5]

The reason it enters the retatrutide conversation is direct: skin laxity is one of the most-searched concerns during rapid weight loss. When body composition changes quickly, skin remodeling can lag, and GHK-Cu's documented role in dermal collagen turnover makes it the peptide researchers reach for on that question.

That gap is the whole point. GHK-Cu having a real role in skin biology does not mean it solves loose skin from a 20%-plus weight reduction, which involves the amount of prior skin stretch, the rate of loss, age, and genetics, none of which a topical or injected tripeptide has been shown to override in that setting. Researchers cite it because it is the most relevant mechanism, not because the outcome is proven.

MOTS-C: the mitochondrial and metabolic angle

MOTS-C is a "mitochondrial-derived peptide," a short peptide encoded within mitochondrial DNA. In mouse studies it activated the AMPK pathway (a central cellular energy sensor), improved insulin sensitivity, promoted metabolic homeostasis, and reduced diet-induced obesity and insulin resistance. ^[6] Later work has explored its role in exercise physiology and its decline with age.

The rationale for discussing it alongside retatrutide is that it targets cellular energy metabolism through a pathway retatrutide does not touch. Retatrutide works at the level of appetite and systemic energy expenditure via receptor agonism; MOTS-C is framed as working further downstream, inside the cell's own energy machinery. In the search data, "MOTS-C vs retatrutide" and "MOTS-C vs GLP-1" are recurring queries: people are actively trying to place it relative to the incretin drugs.

The evidence ceiling is important here: the striking metabolic results are from rodent models, and human data remain preliminary. MOTS-C is a genuinely interesting research target for metabolism, but "interesting research target" is a description of where the science is, not a claim that it adds measurable benefit on top of a triple agonist in humans.

Tesamorelin: the GH axis and visceral fat

Tesamorelin is the outlier in this group. It is a growth-hormone-releasing hormone (GHRH) analog that stimulates the body's own pituitary GH release, and it is the only compound here with a controlled human trial base and an approved human indication (reducing excess visceral fat in HIV-associated lipodystrophy). In those trials it reduced visceral adipose tissue by roughly 15-18% versus placebo ^[7], and follow-up work reported reductions in liver fat as well. ^[8]

Its place in the retatrutide conversation rests on two mechanisms retatrutide does not directly engage: the GH/IGF-1 axis, and a specific effect on visceral (deep abdominal) fat. Because the GH axis is also tied to lean-tissue maintenance and recovery, researchers discussing body composition, not just total weight, cite tesamorelin as the compound that acts through that pathway.

The caveats still apply. Tesamorelin's human data come from a specific clinical population (people with HIV), not from otherwise-healthy research subjects on retatrutide, and stimulating the GH axis carries its own metabolic considerations, including effects on glucose handling. Its stronger evidence base makes it the most substantiated compound in this overview, but "most substantiated relative to the others here" is not the same as "studied in combination with retatrutide," which it has not been.

How researchers think about sequencing and timing

The compounds above operate on different timescales, and that shapes how the stacking conversation treats sequencing, again, as reported rationale, not instruction.

Two principles recur in how careful researchers frame this. First, introduce one variable at a time. Running retatrutide and three add-ons simultaneously makes it impossible to attribute any observed effect, or any side effect, to a specific compound, which defeats the purpose of a research protocol. Second, let the compound with the strongest evidence carry the primary hypothesis. Retatrutide has trial data; the add-ons largely do not. Treating the add-ons as decorative around a well-characterized core keeps the interpretation honest.

The cautions: what stacking does not fix

The most important section is the one that pushes back. The appeal of a stack is the implicit promise that the right combination compounds the benefit, and that promise is exactly where the evidence is thinnest.

• No combination data exist. Every figure in this article comes from a study of a single compound, most in isolation and several in animals. There is no controlled human trial of retatrutide plus BPC-157, plus GHK-Cu, plus MOTS-C, or plus tesamorelin. Additive benefit is an assumption, not a finding.
• Interactions are uncharacterized. More compounds mean more overlapping effects on metabolism, glucose handling, and the GH axis, and none of those interactions has been mapped. Tesamorelin's GH-axis activity and retatrutide's glucose effects, for instance, both touch insulin sensitivity in opposite-seeming ways, and that intersection is simply unstudied.
• Each add-on carries its own uncharacterized risk. Most are investigational research compounds without the safety database that even retatrutide's trial program provides. Stacking multiplies unknowns rather than averaging them out.
• Sourcing quality compounds the problem. Every compound in a stack has to clear the same bar: a batch-matched certificate of analysis, identity and purity confirmed, ideally with independent testing. A stack is only as clean as its least-verified vial.

None of this makes the mechanisms uninteresting. It means the correct posture is research curiosity with a clear map of where the evidence stops, which, for the add-ons, is early.

Where retatrutide fits

The throughline of every section above is that retatrutide is the part with real trial data behind it. Its triple-agonist mechanism and its Phase 2 result are documented; the add-ons are chosen to cover adjacent gaps and rest largely on mechanism and preclinical work. If there is one practical takeaway from the stacking conversation, it is to keep the well-characterized compound at the center and treat everything else as the frontier it actually is. The complete retatrutide guide covers the core compound's mechanism, trial data, and dosing landscape, and the dosing and titration guide covers why its own schedule is built the way it is. For the underlying biology of why different peptides act on different receptors, see how peptides work.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies of single compounds; none of the peptides discussed here has been studied in combination with retatrutide in humans. Retatrutide and the other compounds referenced are investigational and are not approved for human use.